

Ref No.: SARF/2020-21

Date: 31.08.2020

To,  
The Principal,  
Institute of Pharmaceutical Education and Research,  
Borgaon, Wardha.

Subject: Sample for acute toxicity study.

Dear Sir,

With reference to our discussion, we are sending herewith following samples for acute toxicity.

Sr No.	Name of Product	Batch No.	Mfg Date.	Expiry Date	Weight	Qty in No's
1	Termino Spot on	VTS04	03/2020	02/2023	30 ml	02
2	Respi-SID Poultry	VRPP04	03/2020	02/2023	100 ml	02
3	Renosid Poultry	VRP05	03/2020	02/2023	100 ml	02

Kindly acknowledge the receipt of the same and start the work.

Thanking you.

Yours Faithfully,



S.S. Dhurde

(Authorized Signatory)


Reg. Off. :- 404, Chartered House, Dr. Cawasji Ha

Factory At :-

Bahadura :- Post - Kalmna (Acharya), Umrer Road, B

Wadsa :- Lakhandur Road, Desaijanj Wadsa, - Dist. G



  
(Dr. R. O. Ganjiwale)  
Principal  
PRINCIPAL  
Institute of Pharmaceutical Education & Research  
Borgaon (Meghe), Wardha

278115

# PROJECT REPORT

## ACUTE DERMAL TOXICITY STUDY OF TERMINO SPOT ON

*Submitted to*

*Siddhayu Ayurvedic Research Foundation Pvt. Ltd,  
Nagpur 440 009*

**Submitted By**

**Project coordinator**

**Dr. R. O. Ganjiwale**

I/c Principal

Institute of Pharmaceutical Education and Research,  
Borgaon (Meghe), Wardha

**Principal investigator**

**Dr. B. R. Gandhare**

Associate Professor

Department of Pharmacology,  
Institute of Pharmaceutical Education and Research,  
Borgaon (Meghe), Wardha



**Performing Department**

Department of Pharmacology,  
Institute of Pharmaceutical Education and Research,  
Borgaon (Meghe), Wardha

SEPETM



*(Dr. R. O. Ganjiwale)*  
Principal  
PRINCIPAL  
Institute of Pharmaceutical Education & Research  
Borgaon (Meghe), Wardha

## REPORT

### STUDY TITLE

# ACUTE DERMAL TOXICITY STUDY OF TERMINO SPOT ON

### Sponsored by

Siddhayu Ayurvedic Research Foundation Pvt. Ltd,  
Nagpur 440 009

### Submitted to

Siddhayu Ayurvedic Research Foundation Pvt. Ltd,  
Nagpur 440 009

Date of commencement: 8<sup>th</sup> September 2020 to 24<sup>th</sup> September 2020

### Project coordinator

**Dr. R. O. Ganjiwale**

I/c Principal

Institute of Pharmaceutical Education and Research,  
Borgaon (Meghe), Wardha

### Principal investigator

**Dr. B. R. Gandhare**

Associate Professor

Department of Pharmacology,  
Institute of Pharmaceutical Education and Research,  
Borgaon (Meghe), Wardha

### Co-Principal Investigator

**Mr. Jyotiranjana Roul**

Assistant Professor

Department of Pharmacology,  
Institute of Pharmaceutical Education and Research,  
Borgaon (Meghe), Wardha



  
(Dr. R. O. Ganjiwale)

Principal


PRINCIPAL

Institute of Pharmaceutical Education & Research  
Borgaon (Meghe), Wardha

## TABLE OF CONTENT

SR. NO.	TITLE	PAGE NO.
1.	INTRODUCTION	4
2.	MATERIALS AND METHODS	4
3.	RESULTS	8
4.	DISCUSSION	12
5.	CONCLUSION	12
6.	REFERENCE	13



  
(Dr. R. O. Ganjiwale)  
Principal  
PRINCIPAL  
Institute of Pharmaceutical Education & Research  
Borgnour (Moghe), Wardha

### LIST OF TABLES

TABLE NO.	TITLE	PAGE NO.
1.	GROUPS OF ANIMALS	5
2.	MEAN BODY WEIGHT	8
3.	MORTALITY	8
4.	FOOD CONSUMPTION (g / animal)	9
5.	BIOCHEMICAL FINDING	9
6.	PATHOLOGY FINDINGS	9

### LIST OF PLATES

PLATE NO.	TITLE	PAGE NO.
1.	Histopathological Studies of Liver (Group II (2000 mg/kg) (H&E) X100	10
2.	Histopathological Studies of Kidney (Group II (2000 mg/kg) (H&E) X100	10
3.	Histopathological Studies of Lung (Group II (2000 mg/kg) (H&E) X400	11
4.	Histopathological Studies of Heart (Group II 2000 mg/kg) X400	11



## 1. INTRODUCTION

Acute dermal toxicity is the adverse effects occurring within a short time of dermal application of a single dose of a test substance. In the assessment and evaluation of the toxic characteristics of a substance, determination of acute dermal toxicity is useful where exposure by the dermal route is likely. It provides information on health hazards likely to arise from a short-term exposure by the dermal route. Data from an acute dermal toxicity study may serve as a basis for classification and labelling. It is an initial step in establishing a dosage regimen in subchronic and other studies and may provide information on dermal absorption and the mode of toxic action of a substance by this route. (OECD Guideline 402)

### OBJECTIVE:

To determine the acute dermal toxicity (if any) of the test sample **Termino Spot on** (Batch No. VTS04) supplied by Siddhayu Ayurvedic Research Foundation Pvt. Ltd, Nagpur.

### PRINCIPLE:

The test substance is applied to the skin in graduated doses to several groups of experimental animals, one dose being used per group. Subsequently, observations of effects and deaths are made. Animals which die during the test are necropsied. The surviving animals are sacrificed and necropsied. Animals showing severe and enduring signs of distress and pain may need to be humanely killed. Dosing test substances in a way known to cause marked pain and distress due to corrosive or irritating properties need not be carried out. (OECD Guideline 402)

## 2. MATERIALS AND METHODS

**Test Substance:** The supplier provided for the test container containing cream identified as **Termino Spot on** (Batch No. VTS04)

The test substance was stored at ambient temperature and out of the light

### Details of test animals


**Species:** Albino rats weighing in range of 220-240 g

**Strain:** Wistar

**Sex:** Female

**Number of animals per dose level:** 3



  
(Dr. R. O. Ganjivale)  
Principal  
PRINCIPAL  
Institute of Pharmaceutical Education & Research  
Borguon (Mighe), Wardha

**Number of groups:** 2

**Selected doses:** 200 and 2000 mg/kg

**Rationale of selection:** As per OECD 402 guidelines

**Housing and feeding conditions**

Animals were caged individually. The temperature of the experimental animal room was 22°C ( $\pm$  3°) and the relative humidity 30-70 per cent. Cages maintained at 12 hr of light and dark cycle in the animal house of the Institute.

**Diet:** Standard feed prepared in-house.

**Water:** Plain tap water *ad libitum*.

**Allocation of animals to various groups:**

**Table No. 1. GROUPS OF ANIMALS**

Group No.	Dose (mg/kg b. Wt) Topically	Animal Numbers
I	200	1 - 3
II	2000	4 - 6

### Preparations

Healthy young adult rats were acclimatized to the laboratory conditions for 5 days prior to the test. Before the test, animals were randomized and assigned to the treatment groups. Approximately 24 hours before the test, fur was removed from the dorsal area of the trunk of the test animals by shaving. Care was taken to avoid abrading the skin, which could alter its permeability.

About 10 per cent of the body surface area was clear for the application of the test substance.

### EXPERIMENTAL:

The animals were fasted overnight prior to dosing but water was not withheld. Following the period of fasting, the animal was randomized and assigned to the treatment groups. The test substance was applied on the fur-removed skin. After treatment, the animals were observed for 14 days. Water was withheld for 1-2 hours. If the compound are



*(Signature)*  
(Dr. R. O. Ganjivale)  
Principal  
PRINCIPAL  
Institute of Pharmaceutical Education & Research  
Borgoo (Moghe), Wardha

only above regulatory limit dose then, the dose level to be used as the starting dose is selected as 200 mg/kg b. wt. Accordingly, the first dose in this study was 200 mg/kg (topically) and after that as no toxicity occurred; a limit test dose of 2000 mg/kg b. wt. (topically) was taken. Body weight of the entire test animal was recorded before and periodically (weekly) after administration of the test sample. The animal were observed for 24 hours, then for further 1 days for death and manifestation of toxic effects like changes in skin and fur, eyes and mucous membranes and also any changes in respiratory, circulatory, CNS, autonomic, somatic activity and behaviour pattern if any was recorded. The important clinical sign like muscular tremors, convulsions, salivation, diarrhea, lethargy, sleep and coma if any observed during study period were recorded.

### Acute Dermal Toxicity (OECD-402)

For the product of topical application, the testing was undertaken as per OECD-402 guidelines to conduct acute dermal toxicity study test. The Original acute dermal toxicity guideline 402 was adopted in 1987. In this study, both local and systemic effects were investigated. For acute dermal toxicity test 06 Wister rats were procured from CPCSEA registered breeding source i.e. Small Animal Facility, of I.P.E.R, Wardha and the test was conducted as per OECD-402 guidelines.

### OBSERVATIONS:

The animals were clinically observed twice on the day of the dosing and once daily thereafter for 14 days.


#### 1. Clinical signs:

All animals were observed daily for clinical signs such as gross changes in the activity and the behavioral pattern. They were also observed for the presence of tremors, convulsions, salivation, diarrhea and lethargy

#### 2. Body weight:

The mean group body weight of  
0<sup>th</sup> day, 7<sup>th</sup> day and 14<sup>th</sup> day.



  
(Dr. R. O. Ganjivale)  
Principal  
PRINCIPAL  
Institute of Pharmaceutical Education & Research  
Borguon (Moghe), Wardha

recorded on

#### 3. Mortality:

All animals were observed twice daily for mortality during the period of the study.



#### 4. Food consumption:

The quantities of food consumed by control and test groups were recorded on 0<sup>th</sup> day, 7<sup>th</sup> day and on 14<sup>th</sup> day.

#### 5. Biochemical Parameters:

- Aspartate aminotransferase (AST),
- Alanine transaminase (ALT),
- Alkaline phosphatase (ALP),
- Creatinine

#### 6. Gross pathology and Histopathology:

All the animals surviving at the end of the 14 days of observation were scarified by intraperitoneal injection of 6% sodium pentobarbital solution at the rate of 0.12 ml/100g and bled at the femoral artery. They were necropsied and the main organs were examined macroscopically. Gross pathology and histopathological examination of lung, Liver, Kidney, and heart were conducted.


**Interpretation of the results:** The assessment criteria of the toxicity of the test substance taken into account were:

- Body weight change
- Clinical and behavioral signs
- Necropsy findings histopathological examination
- The mortality expressed in % of compound related deaths.

These results enabled to classify the test substance to one of a series of toxicity classes defined by fixed oral LD<sub>50</sub> cut-off values, in compliance with Globally Harmonized System (GHS).

- Category 1 = 0 < LD<sub>50</sub> < 5 mg/kg
- Category 2 = 5 mg/kg
- Category 3 = 50 mg/kg
- Category 4 = 300 mg/kg
- Category 5 = LD<sub>50</sub> > 2000 mg/kg
- Category 5 or non classified



  
(Dr. R. O. Ganjivale)  
Principal  
PRINCIPAL  
Institute of Pharmaceutical Education & Research  
Borgun (Moghe), Wardha

### 3. RESULTS

#### Clinical signs:

All the groups were free of intoxication signs throughout the period of study.

#### Body weight:

Animals from control and test groups exhibited normal and comparable body weight gain throughout the period of study. (Table No. 2)

**Table No. 2 INDIVIDUAL BODY WEIGHT**

Group No.	Dose (mg/kg) Topically	Rats No.	Body weight (g)		
			0 <sup>th</sup> day	7 <sup>th</sup> day	14 <sup>th</sup> day
I	200	1	220	228	234
		2	225	234	240
		3	220	229	240
		<b>Mean±SD</b>	221.67±289	230.33±3.21	238.00±3.46
II	2000	4	234	242	249
		5	230	238	245
		6	221	231	240
		<b>Mean±SD</b>	228.33±6.66	237±5.57	244.67±4.51

Values expressed as mean ± standard deviation

#### Mortality: (Table No. 3)

All animals from control group and test group survived throughout the study for 14 days.

**Table No. 3 MORTALITY**

Under the condition of the present study, the following mortality rates were recorded

Group No.	Dose (mg/kg) Body weight (g)	Mortality
I		
II		



(Dr. R. O. Ganjiwale)  
Principal  
PRINCIPAL  
Institute of Pharmaceutical Education & Research  
Borguou (Meghe), Wardha

Food consumption

Table No. 4 GROUP MEAN FOOD CONSUMPTION (g / animal)

Group No.	Dose (mg/kg)	Day		
		0 <sup>th</sup>	7 <sup>th</sup>	14 <sup>th</sup>
I	200	11	14	15
II	2000	12	14	13

Biochemical Parameter

Table No. 5: BIOCHEMICAL FINDING

Group No.	Dose	AST (IU/L)	ALT (IU/L)	ALP (IU/L)	Creatinine (mg/dL)
I	200 mg/ kg b. wt topically	49.67±2.52	68.00±5.29	77.67±7.51	1.37±0.15
II	2000 mg/ kg b. wt topically	59.67.33±2.52	81.67±2.08	84.67±4.93	1.47±0.32
Significance /NS		NS	NS	NS	NS

Values are expressed as mean ± SD, NS=Non significant

**Gross pathology:** All main organs subjected to necropsy were found normal in all animals. The result of the necropsy findings are summarized in the table 5.

Table No. 6 PATHOLOGY FINDINGS

Group No.	Death		Comments
	Day	Reason	
I	Day 15	Sacrifice	NTR
II	Day 15	Sacrifice	NTR

NTR = nothing to report

**Histopathology:** Section from liver



(Dr. R. O. Ganjivale)  
Principal  
PRINCIPAL  
Institute of Pharmaceutical Education & Research  
Borgoo (Moghe), Wardha

n with mild


perivascular lymphoid aggregation. Section from kidney and heart are unremarkable. Section from Lung shows mild pneumonitis.



PLATES



Plate 1: Histopathological Studies of Liver (Group II (2000 mg/kg) (H&E) X100



*(Dr. R. O. Ganjiwale)*  
Principal  
PRINCIPAL  
Institute of Pharmaceutical Education & Research  
Borguon (Meghe), Wardha

Plate 2: Histopathological Studies of Kidney (Group II (2000 mg/kg)  
(H&E) X100





**Plate 3: Histopathological Studies of Lung (Group II (2000 mg/kg) (H&E) X400**



*Dr. R. O. Ganjiwale*  
(Dr. R. O. Ganjiwale)  
Principal  
PRINCIPAL  
Institute of Pharmaceutical Education & Research  
Borgnon (Meghe), Wardha

**Plate 4: Histopathological Studies of Heart (Group II 2000 mg/kg) X400**

#### 4. DISCUSSION:


1. The animals treated at different dose levels with the above test compound Termino Spot on (Batch No. VTS04) in all the groups exhibited normal activity and behavioral pattern.
2. There were no clinical signs of tremors, convulsions, exophthalmia, salivation, diarrhea and lethargy.
3. Animals exhibited normal and comparable body weight gain throughout the period of study.
4. Food intake of normal and animals treated at different dose levels was found to be comparable throughout the tenure of the study.
5. The pathology finding shows no abnormality in any group of animals.

#### 5. CONCLUSION:

The above findings revealed that the Termino Spot on (Batch No. VTS04) supplied by Siddhayu Ayurvedic Research Foundation Pvt. Ltd, Nagpur was found to be safe at doses 200 and 2000 mg/kg when applied locally. None of the animals were found to be moribund condition in all the groups until the 14 days of the study.

The Study has indicated that Termino Spot on (Batch No. VTS04) at dose of 2000 mg/kg did not affect general health of Wistar rats. There were no gross abnormalities observed in necropsied rats. Based on this, minimal lethal dose of Termino Spot on (Batch No. VTS04) was more than 2000 mg/kg.



  
(Dr. R. O. Ganjivale)  
Principal  
PRINCIPAL  
Institute of Pharmaceutical Education & Research  
Borgun (Moghe), Wardha

## REFERENCES

1. OECD Guideline for Testing of Chemicals, Acute oral Toxicity – Fixed Dose Procedure, 402. Organization for Economic Co-operation and Development, Paris, 9<sup>th</sup> October 2017.
2. OECD – Harmonized Integrated Hazard Classification System for Human Health and Environmental Effects of Chemical Substances – as endorsed by the 28<sup>th</sup> Joint Meeting of the Chemicals Committee and the Working Party on Chemicals, November 1998.
3. OECD (2000) – Guidance Document on the Recognition Assessment and Use of Clinical Signs as Humane Endpoints for Experimental Animals Used in Safety Evaluation. Environmental Health and Safety Monograph Series on Testing and Assessment No. 19.

**Project coordinator**

: Dr. R. O. Ganjiwale  
I/c Principal  
I.P.E.R. Wardha



**PRINCIPAL**

Institute of Pharmaceutical Education & Research  
Borgaon (Meghe), Wardha.


**Principal Investigator**

: Dr. B. R. Gandhare  
Associate Professor  
I.P.E.R. Wardha



**Co-Principal Investigator**



  
(Dr. R. O. Ganjiwale)  
Principal  
**PRINCIPAL**  
Institute of Pharmaceutical Education & Research  
Borgaon (Meghe), Wardha





# PROJECT REPORT

## ACUTE ORAL TOXICITY TEST IN THE RATS -Fixed Dose Procedure-

*Submitted to*

*Siddhayu Ayurvedic Research Foundation Pvt. Ltd,  
Nagpur 440009*

**Submitted By**

**Project coordinator**

**Dr. R. O. Ganjiwale**

I/c Principal

Institute of Pharmaceutical Education and Research,  
Borgaon (Meghe), Wardha

**Principal investigator**

**Dr. B. R. Gandhare**

Associate Professor

Department of Pharmacology,  
Institute of Pharmaceutical Education and Research,  
Borgaon (Meghe), Wardha



Department of Pharmacology  
Institute of Pharmaceutical Education and Research,  
Borgaon (Meghe), Wardha



*(Signature)*  
(Dr. R. O. Ganjiwale)  
Principal  
PRINCIPAL  
Institute of Pharmaceutical Education & Research  
Borgaon (Meghe), Wardha

SEPTEMBER 2020



# REPORT

## STUDY TITLE

### ACUTE ORAL TOXICITY TEST IN THE RATS -Fixed Dose Procedure-

#### Sponsored by

Siddhayu Ayurvedic Research Foundation Pvt. Ltd.  
Nagpur, 440009

#### Submitted to

Siddhayu Ayurvedic Research Foundation Pvt. Ltd.  
Nagpur, 440009

Date of commencement: 14<sup>th</sup> September 2020 to 28<sup>th</sup> September 2020

#### Project coordinator

**Dr. R. O. Ganjiwale**

I/c Principal

Institute o Pharmaceutical Education and Research,  
Borgaon (Meghe), Wardha

#### Principal investigator

**Dr. B. R. Gandhare**

Associate Professor


Department of Pharmacology,  
Institute o Pharmaceutical Education and Research,  
Borgaon (Meghe), Wardha

Cc



Def


Institute o Pharmaceutical Education and Research,  
Borgaon (Meghe), Wardha

  
(Dr. R. O. Ganjiwale)  
Principal  
PRINCIPAL  
Institute of Pharmaceutical Education & Research  
Borgaon (Meghe), Wardha

## CONTENTS

<b>I. AIM AND OBJECTIVES</b>	<b>3</b>
<b>II. TEST SUBSTANCE</b>	<b>3</b>
<b>III. TEST ANIMALS</b>	<b>4</b>
<b>IV. TEST PROCEDURE</b>	<b>4</b>
<b>V. OBSERVATIONS</b>	<b>5</b>
<b>VI. RESULTS</b>	<b>6</b>
<b>VII. CONCLUSION</b>	<b>6</b>
<b>VIII. REFERENCES</b>	<b>7</b>
<b>APPENDICES</b>	



  
(Dr. R. O. Ganjiwale)  
Principal  
PRINCIPAL  
Institute of Pharmaceutical Education & Research  
Borgun (Meghe), Wardha

## ***ACUTE ORAL TOXICITY TEST IN THE RATS – FIXED DOSE PROCEDURE METHOD- OECD GUIDELINE 420<sup>1</sup>***

### **I. AIM & OBJECTIVE OF THE TEST**

The aim of the test is to obtain, using a minimum number of animals, sufficient information on the acute toxicity after single administration, by oral route in the rat, of a test substance, for its classification.

The test substance is administered to a group of experimental animals, by oral route at one defined dose (5 mg/kg, 50 mg/kg, 300 mg/kg or 2000 mg/kg) according to the available information on the test substance.

The animals are observed each day for 14 days at least, after administration, to detect the signs of toxicity. Animals which die are necropsied; the animals which are intercurrently sacrificed as well as the ones which survive until the end of the test are necropsied.


This test using pre-defined doses provides results allowing the test substance to be ranked according to the Globally Harmonised System (GHS) for classification of chemicals which cause acute toxicity (OECD 1998).<sup>2</sup>

### **II. TEST SUBSTANCE**

The supplier provided for the test container containing liquid preparation identified as **Respi-SID Poultry** (Batch No. VRPP04).

The test substance was stored at ambient temperature and out of the light.



  
(Dr. R. O. Ganjivale)  
Principal  
PRINCIPAL  
Institute of Pharmaceutical Education & Research  
Borgun (Moghe), Wardha

### III. TEST ANIMALS

**Species:** Albino rats weighing in range of 180-200 g

**Strain:** Wister

**Age:** 8-12 weeks

**Number & Sex:** 5 nulliparous and non-pregnant females.

**Diet:** Standard feed prepared in-house.

**Water:** Plain tap water *ad libitum*.

**Housing:** The animals were housed in 37cm x 23cm x 16cm polypropylene cages with maximum 3 animals per cage. The cages were placed in limited-access premises of animal house with controlled temperature and humidity. The artificial lighting ensured a sequence of 12 hours light and 12 hours dark.

### IV. TEST PROCEDURE

**Preparation of the test substance:** As per information provided by sponsor, the provided liquid formulation is concentrated and should be used with dilution. The highest dose of formulation that can be used is 250 ml in 1000 liter water. So the test substance was diluted accordingly.

**Administration of the test substance:** The animals fasted overnight prior to the test substance administration. All animals were weighed again on day 1 before administration.


The volume per 100 g of body weight, defined to 2 ml/100g, the volume to administer was calculated for each rat.

The test substance was administered in a single dose, orally by gavage using a syringe fitted with suitable sized canula. After administration, animals were fasted for 3-4 hours.

**Selection of starting dose:** As per information provided by sponsor, the provided liquid formulation the starting dose was selected as 2ml/100g of body weight.

**Main study:** According to the OECD guideline 420 (joined in Appendix IV of the present report) the test was performed with 5 animals receiving the test substance at the dose level of 2ml/100g of body weight.



  
(Dr. R. O. Ganjivale)  
Principal  
Institute of Pharmaceutical Education & Research  
Borgun (Moghe), Wardha



## V. OBSERVATIONS

Animals were observed individually after dosing during the first 30 minutes, periodically during the first 24 hours and daily thereafter for a total of 14 days.

The clinical observations were made individually, each animal being examined outside the home cage.

The different parameters observed were – changes in skin & fur, eyes & mucous membranes, respiratory function, tremors, convulsions, salivation, diarrhea, lethargy, sleep & coma.<sup>3</sup>

**Body weight:** The animals were regularly weighed on day 1 before administration, then on day 8 and day 15 i.e. 7 and 14 days after administration of the test substance.

**Pathology:** All the animals surviving at the end of the 14 days of observation were sacrificed by intraperitoneal injection of 6% sodium pentobarbital solution at the rate of 0.12 ml/100g and bled at the femoral artery. They were necropsied and the main organs were examined macroscopically.

**Interpretation of the results:** The assessment criteria of the toxicity of the test substance taken into account were:

- Body weight change
- Clinical and behavioral signs
- Necropsy findings
- The mortality expressed in % of compound related deaths.

These results enabled to classify the test substance to one of a series of toxicity classes defined by fixed oral LD<sub>50</sub> cut-off values, in compliance with Globally Harmonized System (GHS).<sup>2</sup>

- Category 1 = 0 < LD<sub>50</sub> < 5 mg/kg

- Category 2 = 5 mg/kg < LD<sub>50</sub> < 50 mg/kg


- Category 3 = 50 mg/kg < LD<sub>50</sub> < 300 mg/kg

- Category 4 = 300 mg/kg

- Category 5 = LD<sub>50</sub> >

- Category 5 or non class



  
(Dr. R. O. Ganjivale)  
Principal  
PRINCIPAL  
Institute of Pharmaceutical Education & Research  
Borgooon (Moghe), Wardha

## VI. RESULTS

**Body weight:** All animals exhibited normal and comparable body weight gain throughout the period of study. The individual weights of the animals assessed during the test are supplied in Appendix I.

**Clinical Observations:** All animals were free of intoxication signs throughout the period of study. The results of the clinical observations are summarized in the table enclosed in Appendix II.

**Pathology:** All main organs subjected to necropsy were found normal in all animals. The result of the necropsy findings are summarized in the table enclosed in Appendix III.


## VII. CONCLUSION

According to the Globally Harmonized System (GHS) for the classification of substances which cause acute toxicity, the substance **Respi-SID Poultry** (Batch No. VRPP04), supplied by Siddhayu Ayurvedic Research Foundation Pvt. Ltd., Nagpur was classified in the hazard category 5 or unclassified with a LD<sub>50</sub> higher than 2000 mg/kg in the Rat.

The Study has indicated that **Respi-SID Poultry** (Batch No. VRPP04) at dose of 2000mg/kg did not affect general health of Wistar rats. There were no gross abnormalities observed in necropsied rats. Based on this, minimal lethal dose of **Respi-SID Poultry** (Batch No. VRPP04) was more than 2000 mg/kg.

**Project coordinator**


: Dr. R. O. Ganjiwale  
I/c Principal  
I.P.E.R. Wardha

  
**PRINCIPAL**  
Institute of Pharmaceutical Education & Research  
Borgaon (Meghe), Wardha

**Principal investigator**

• Dr. R. R. Gandhare



  
(Dr. R. O. Ganjiwale)  
Principal  
PRINCIPAL  
Institute of Pharmaceutical Education & Research  
Borgaon (Meghe), Wardha

**Co-Principal Investigator**

: Mr. Jyotiranjana Roul  
Assistant Professor  
I.P.E.R. Wardha



# PROJECT REPORT

## ACUTE ORAL TOXICITY TEST IN THE RATS -Fixed Dose Procedure-

*Submitted to*

*Siddhayu Ayurvedic Research Foundation Pvt. Ltd,  
Nagpur 440009*

**Submitted By**

**Project coordinator**

**Dr. R. O. Ganjiwale**

**I/c Principal**

**Institute of Pharmaceutical Education and Research,  
Borgaon (Meghe), Wardha**

**Principal investigator**

**Dr. B. R. Gandhare**

**Associate Professor**

**Department of Pharmacology,  
Institute of Pharmaceutical Education and Research,  
Borgaon (Meghe), Wardha**



Department of Pharmacology  
Institute of Pharmaceutical Education and Research,  
Borgaon (Meghe), Wardha



*(Signature)*  
(Dr. R. O. Ganjiwale)  
Principal  
PRINCIPAL  
Institute of Pharmaceutical Education & Research  
Borgaon (Meghe), Wardha

SEPTEMBER 2020

# REPORT

## STUDY TITLE

### ACUTE ORAL TOXICITY TEST IN THE RATS -Fixed Dose Procedure-

#### Sponsored by

Siddhayu Ayurvedic Research Foundation Pvt. Ltd.  
Nagpur, 440009

#### Submitted to

Siddhayu Ayurvedic Research Foundation Pvt. Ltd.  
Nagpur, 440009

Date of commencement: 14<sup>th</sup> September 2020 to 28<sup>th</sup> September 2020

#### Project coordinator

**Dr. R. O. Ganjiwale**

I/c Principal

Institute o Pharmaceutical Education and Research,  
Borgaon (Meghe), Wardha

#### Principal investigator

**Dr. B. R. Gandhare**

Associate Professor


Department of Pharmacology,  
Institute o Pharmaceutical Education and Research,  
Borgaon (Meghe), Wardha

Co-



Dep:

Institute o Pharmaceutical Education and Research,  
Borgaon (Meghe), Wardha


  
(Dr. R. O. Ganjiwale)  
Principal  
PRINCIPAL  
Institute of Pharmaceutical Education & Research  
Borgaon (Meghe), Wardha



## CONTENTS

<b>I. AIM AND OBJECTIVES</b>	<b>3</b>
<b>II. TEST SUBSTANCE</b>	<b>3</b>
<b>III. TEST ANIMALS</b>	<b>4</b>
<b>IV. TEST PROCEDURE</b>	<b>4</b>
<b>V. OBSERVATIONS</b>	<b>5</b>
<b>VI. RESULTS</b>	<b>6</b>
<b>VII. CONCLUSION</b>	<b>6</b>
<b>VIII. REFERENCES</b>	<b>7</b>
<b>APPENDICES</b>	



  
(Dr. R. O. Ganjiwale)  
Principal  
PRINCIPAL  
Institute of Pharmaceutical Education & Research  
Borgoo (Moghe), Wardha

## **ACUTE ORAL TOXICITY TEST IN THE RATS – FIXED DOSE PROCEDURE METHOD- OECD GUIDELINE 420<sup>1</sup>**

### **I. AIM & OBJECTIVE OF THE TEST**

The aim of the test is to obtain, using a minimum number of animals, sufficient information on the acute toxicity after single administration, by oral route in the rat, of a test substance, for its classification.

The test substance is administered to a group of experimental animals, by oral route at one defined dose (5 mg/kg, 50 mg/kg, 300 mg/kg or 2000 mg/kg) according to the available information on the test substance.

The animals are observed each day for 14 days at least, after administration, to detect the signs of toxicity. Animals which die are necropsied; the animals which are intercurrently sacrificed as well as the ones which survive until the end of the test are necropsied.


This test using pre-defined doses provides results allowing the test substance to be ranked according to the Globally Harmonised System (GHS) for classification of chemicals which cause acute toxicity (OECD 1998).<sup>2</sup>

### **II. TEST SUBSTANCE**

The supplier provided for the test container containing liquid preparation identified as **Renosid Poultry** (Batch No. VI)

The test substance was stored at



  
(Dr. R. O. Ganjivale)  
Principal  
PRINCIPAL  
Institute of Pharmaceutical Education & Research  
Borgaon (Moghe), Wardha

### III. TEST ANIMALS

**Species:** Albino rats weighing in range of 180-200 g

**Strain:** Wister

**Age:** 8-12 weeks

**Number & Sex:** 5 nulliparous and non-pregnant females.

**Diet:** Standard feed prepared in-house.

**Water:** Plain tap water *ad libitum*.

**Housing:** The animals were housed in 37cm x 23cm x 16cm polypropylene cages with maximum 3 animals per cage. The cages were placed in limited-access premises of animal house with controlled temperature and humidity. The artificial lighting ensured a sequence of 12 hours light and 12 hours dark.

### IV. TEST PROCEDURE

**Preparation of the test substance:** The test substance was administered without dilution.

**Administration of the test substance:** The animals fasted overnight prior to the test substance administration. All animals were weighed again on day 1 before administration.

The volume per 100 g of body weight, defined to 2 ml/100g, the volume to administer was calculated for each rat.


The test substance was administered in a single dose, orally by gavage using a syringe fitted with suitable sized canula. After administration, animals were fasted for 3-4 hours.

**Selection of starting dose:** As the test substance was an Ayurvedic formulation the starting dose was selected as 2m

**Main study:** According to the guideline 420 (joined in Appen

with 5 animals receiving the test substance at the dose level of 2000/100g of body weight.



  
(Dr. R. O. Ganjwale)  
Principal  
PRINCIPAL  
Institute of Pharmaceutical Education & Research  
Borgaon (Meghe), Wardha

the OECD  
performed

## V. OBSERVATIONS

Animals were observed individually after dosing during the first 30 minutes, periodically during the first 24 hours and daily thereafter for a total of 14 days.

The clinical observations were made individually, each animal being examined outside the home cage.

The different parameters observed were – changes in skin & fur, eyes & mucous membranes, respiratory function, tremors, convulsions, salivation, diarrhea, lethargy, sleep & coma.<sup>1</sup>

**Body weight:** The animals were regularly weighed on day 1 before administration, then on day 8 and day 15 i.e. 7 and 14 days after administration of the test substance.

**Pathology:** All the animals surviving at the end of the 14 days of observation were sacrificed by intraperitoneal injection of 6% sodium pentobarbital solution at the rate of 0.12 ml/100g and bled at the femoral artery. They were necropsied and the main organs were examined macroscopically.


**Interpretation of the results:** The assessment criteria of the toxicity of the test substance taken into account were:

- Body weight change
- Clinical and behavioral signs
- Necropsy findings
- The mortality expressed in % of compound related deaths.

These results enabled to classify the test substance to one of a series of toxicity classes defined by fixed oral LD<sub>50</sub> cut-off values, in compliance with Globally Harmonized System (GHS).<sup>2</sup>

- Category 1 = 0 < LD<sub>50</sub> < 5 mg/kg
- Category 2 = 5 mg/kg < LD<sub>50</sub> < 50 mg/kg
- Category 3 = 50 mg
- Category 4 = 300 mg
- Category 5 = LD<sub>50</sub>
- Category 5 or non classified



  
(Dr. R. O. Ganjiwale)  
Principal  
PRINCIPAL  
Institute of Pharmaceutical Education & Research  
Borgoa (Moghe), Wardha

## VI. RESULTS

**Body weight:** All animals exhibited normal and comparable body weight gain throughout the period of study. The individual weights of the animals assessed during the test are supplied in Appendix I.

**Clinical Observations:** All animals were free of intoxication signs throughout the period of study. The results of the clinical observations are summarized in the table enclosed in Appendix II.


**Pathology:** All main organs subjected to necropsy were found normal in all animals. The result of the necropsy findings are summarized in the table enclosed in Appendix III.

## VII. CONCLUSION

According to the Globally Harmonized System (GHS) for the classification of substances which cause acute toxicity, the substance **Renosid Poultry** (Batch No. VRP05), supplied by Siddhaya Ayurvedic Research Foundation Pvt. Ltd., Naggur was classified in the hazard category 5 or unclassified with a LD<sub>50</sub> higher than 2000 mg/kg in the Rat.

The Study has indicated that **Renosid Poultry** (Batch No. VRP05) at dose of 2000mg/kg did not affect general health of Wistar rats. There were no gross abnormalities observed in necropsied rats. Based on this, minimal lethal dose of **Renosid Poultry** (Batch No. VRP05) was more than 2000 mg/kg.


**Project coordinator** : Dr. R. O. Ganjiwale  
I/c Principal  
I.P.E.R. Wardha



**PRINCIPAL**

Institute of Pharmaceutical Education & Research  
Borgaon (Meghe), Wardha.

**Principal investigator**



(Dr. R. O. Ganjiwale)  
Principal  
PRINCIPAL  
Institute of Pharmaceutical Education & Research  
Borgaon (Meghe), Wardha

**Co-Principal Investigator** : Mr. Jyotiranjn Roul  
Assistant Professor  
I.P.E.R. Wardha

